COMMUNIQUÉS West-GlobeNewswire

Herz P1 Smart Oximeter Claims Evaluated: Best Pulse Oxygen Monitor Device on the Market with Clinical-Grade Accuracy
19/04/2026
A 2026 informational report on the Herz P1 Smart Oximeter fingertip pulse oxygen monitor, covering the company's FDA 510(k) cleared positioning, ±2% SpO2 blood oxygen accuracy specifications, smart alarm alert features [...]
Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation
18/04/2026
A 2026 informational overview of Vigor Boost Gummies ingredient disclosures, proprietary blend structure, label-vs-marketing discrepancies, ForceVital male enhancement positioning, and what men should verify before [...]
SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss
18/04/2026
A 2026 informational report on the SlimLeaf Akkermansia probiotic gut health formula, FitBurn weight management ingredient research, Slim Leaf supplement facts, CFU dosing context, pricing, and what consumers should [...]
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
18/04/2026
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR’s Clinical Trials Mini [...]
MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy
18/04/2026
Federal action signals growing recognition of psychedelic therapies’ potential to address urgent mental health challenges, including PTSD, depression, and substance use disorders Expanding research must be paired with [...]
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
18/04/2026
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability [...]
Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe
18/04/2026
ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe Première étude comparative de phase 4, randomisée, en double aveugle, [...]
VigoSurge Claims Evaluated: Analyzing the Ingredients' Benefits, Side Effects Risk and Customer Complaints
18/04/2026
A consumer information release covering what VigoSurge states about its 14-ingredient male health formula, including ingredient descriptions, side effects considerations, refund policy details, and commonly searched [...]
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
18/04/2026
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study [...]
VidaCalm Claims Evaluated: Analyzing the Formula's Ingredients, Side Effects Risk and User Complaints
18/04/2026
A 2026 structured overview of VidaCalm's 18-ingredient hearing support formula, ingredient research context, safety considerations, and what consumers searching for tinnitus relief should verify before purchasing Aurora [...]
Steel Flow Pro Claims Evaluated: Analyzing the Prostate Support Ingredients, Side Effects Risk and Hidden Complaints
18/04/2026
A 2026 consumer information release on Steel Flow Pro prostate support ingredients, Graminex flower pollen extract, saw palmetto, label disclosures, and what men should verify before ordering Largo, FL, April 17, 2026 ( [...]
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
17/04/2026
REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
4DMT Announces New Employment Inducement Grants
17/04/2026
EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
17/04/2026
Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptor OP-3136, in combination with palazestrant, exhibits synergistic anti-tumor [...]
Keeps Hair Growth Product Claims Evaluated: Topical & Oral RX Hair Loss Prescription Treatment with Finasteride, Dutasteride & Minoxidil
17/04/2026
A 2026 informational overview of how the Keeps telehealth platform presents finasteride, dutasteride, and minoxidil prescription hair loss treatment options, clinician-guided plan formats, pricing structure, and what [...]
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
17/04/2026
XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with Xilio’s clinically-validated masking technology, XTX601 was well tolerated [...]
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
17/04/2026
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with [...]
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/04/2026
CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
17/04/2026
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company [...]

Pages